Sugi Predict

Sugi Predict / Compounds / SCHEMBL7007408

SCHEMBL7007408

SCHEMBL7007408

CCOC(=O)CCN1CCN(C(=O)OCc2ccccc2)CC1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TMEM97 Q5BJF2 11/20 0.56
▸ SIGMAR1 Q99720 10/20 0.56
▸ HRH2 P25021 3/20 0.56
▸ HRH1 P35367 3/20 0.56
▸ SLC6A2 P23975 2/20 0.56
▸ HRH3 Q9Y5N1 2/20 0.56
▸ CHRM1 P11229 1/20 0.56
▸ HTR1A P08908 2/20 0.55
▸ HTR1B P28222 2/20 0.55
▸ HTR2A P28223 2/20 0.55
▸ HTR2C P28335 2/20 0.55
▸ HTR1E P28566 2/20 0.55
▸ HTR2B P41595 2/20 0.55
▸ CHRM5 P08912 1/20 0.55
▸ ADRA1D P25100 1/20 0.55
▸ SLC6A3 Q01959 1/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ NPC1 O15118 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7368700 0.89 RAB9A (0.48) TMEM97SIGMAR1HRH2HRH1SLC6A2
SCHEMBL16475199 0.87 TMEM97 (0.52) TMEM97SIGMAR1HRH2HRH1HRH3
SCHEMBL28429226 0.85 MEN1 (0.48) TMEM97SIGMAR1HRH2HRH1HRH3
SCHEMBL28431069 0.84 MEN1 (0.47) TMEM97SIGMAR1HRH2HRH1HRH3
SCHEMBL3622805 0.83 MEN1 (0.51) TMEM97SIGMAR1HRH2HRH1HRH3
SCHEMBL6487467 0.83 ELANE (0.46) TMEM97SIGMAR1HRH2HRH1HRH3
SCHEMBL28433633 0.83 P2RX7 (0.49) TMEM97SIGMAR1HRH2HRH1HRH3
SCHEMBL4391159 0.82 MEN1 (0.50) TMEM97SIGMAR1HRH2HRH1HRH3
SCHEMBL1088050 0.82 ALDH1A1 (0.48) TMEM97SIGMAR1HRH2HRH1HRH3
SCHEMBL28429220 0.82 USP19 (0.49) TMEM97SIGMAR1HRH2HRH1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1224186-B1 PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION MILLENNIUM PHARM INC (US) 2003-09-24 — — EP disclosed
US-20030055244-A1 Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation MILLENNIUM PHARMACEUTICALS, INC. 2003-03-20 — — US disclosed
EP-1224186-A2 PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION COR THERAPEUTICS, INC. (US) 2002-07-24 — — EP disclosed
WO-2001030780-A2 PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION COR THERAPEUTICS, INC. (US) 2001-05-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055244-A1 Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation PF4, PFKP, FGB TMEM97 3526/4885SIGMAR1 4672/4885HRH2 1409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.